Prophylactic HIV-1 vaccine trials: past, present, and future

An effective HIV -1 vaccine is a global health priority but has remained elusive for more than 40 years. Key scientific hurdles that have hampered vaccine development are the unprecedented genetic variability of the virus, the rapid establishment of persistent viral latency, and the challenges associated with induction of broadly neutralising antibodies. Clinical trials have been instrumental in evaluating scientific concepts and testing vaccine strategies. This Review discusses lessons learned from clinical trials of HIV -1 vaccines, current technologies that are being explored, and future considerations in the development of a safe and effective HIV -1 vaccine.